Mereo BioPharma Group Plc公布的最新财务数据显示,其全年营业收入为50万美元,而此前IBES的预估值为52万美元,实际营收略低于市场预期。
同期,该公司公布的全年营业利润为亏损4010.7万美元。
Mereo BioPharma Group Plc公布的最新财务数据显示,其全年营业收入为50万美元,而此前IBES的预估值为52万美元,实际营收略低于市场预期。
同期,该公司公布的全年营业利润为亏损4010.7万美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.